Patents Examined by Dong Jiang
  • Patent number: 12030949
    Abstract: The present invention relates to combination therapies and to their use in the treatment of chronic airway disease, particularly use in the treatment of asthma. The combination therapies comprise (i) an antagonist of IL-5:IL-5R and (ii) an antagonist of IL-4:IL-4R and/or an antagonist of IL-13:IL-13R. The present invention also provides bispecific antibodies comprising an antigen binding domain that binds to IL-4R? and an antigen binding domain that binds to IL-5. The bispecific antibodies may be used for the treatment of chronic airway disease, particularly asthma.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: July 9, 2024
    Assignee: argenx BV
    Inventors: Christophe Blanchetot, Marie Godar, Bart Lambrecht
  • Patent number: 12012441
    Abstract: Orthogonal IL-21 receptors and orthogonal IL-21 cytokines are described. The IL-21 receptor-cytokine pairs may include an orthogonal interleukin-21 receptor ? chain (“ortho-IL-21R?”) that has impaired binding to native interleukin-21 cytokine (“IL-21”) and an orthogonal IL-21 cytokine (“ortho-IL-21”) that has impaired binding to native IL-21R?, wherein the ortho-IL-21R? binds to the ortho-IL-21. The IL-21 receptor-cytokine pair may activate IL-21 signaling. Cells engineered to express the orthogonal IL-21 receptors are also described, as well as methods for using such cells for treatment of various diseases and disorders.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: June 18, 2024
    Assignee: Neptune Biosciences LLC
    Inventors: Nigel Killeen, Oren Beske, Benedikt K. Vollrath, Sridhar Govindarajan
  • Patent number: 12012442
    Abstract: Disclosed herein is an activatable fusion protein that includes, in an N- to C-terminal direction, an albumin, a matrix metalloproteinase-cleavable linker, and an immunoadhesin which includes a cytotoxic T lymphocyte-associated antigen-4 (CTLA4) having an N-terminal extracellular domain and an IgG Fc region, wherein the albumin is released from the activatable fusion protein in the presence of a matrix metalloproteinase that cleaves the cleavable linker, so that the N-terminal extracellular domain of the CTLA4 binds to CD80 or CD86. Also disclosed herein is use of the activatable fusion protein for suppressing a T cell-dependent immune response.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: June 18, 2024
    Assignee: NATIONAL YANG MING CHIAO TUNG UNIVERSITY
    Inventors: Shey-Cherng Tzou, Yu-Yuan Hsiao, Fu-Yao Jiang, Yan-Zhu Zhang, Chien-Yu Chou
  • Patent number: 11999783
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: June 4, 2024
    Assignee: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Patent number: 11951157
    Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non-agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: April 9, 2024
    Assignee: UNIVERSITAT ZURICH
    Inventors: Burkhard Becher, Johannes Vom Berg
  • Patent number: 11919950
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: March 5, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Patent number: 11911444
    Abstract: The present invention relates generally to compositions for treating patients that have skin cancer or have recently had skin cancers removed. More specifically, the present invention provides human skin substitutes engineered to express exogenous IL-12 and compositions and methods for making human skin substitutes engineered to express exogenous IL-12. In addition, the present invention provides methods for treatment of sites on a patient where skin cancers have been removed with human skin substitutes engineered to express exogenous IL-12.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: February 27, 2024
    Assignee: Stratatech Corporation
    Inventors: Allen R. Comer, B. Lynn Allen-Hoffmann
  • Patent number: 11859001
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human 1LI2RM, compositions comprising such antibodies, and methods of use thereof.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: January 2, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • Patent number: 11840566
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 12, 2023
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • Patent number: 11834472
    Abstract: An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: December 5, 2023
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang, William Boyle
  • Patent number: 11773159
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: October 3, 2023
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • Patent number: 11744877
    Abstract: The present invention provides a tumour vasculature permeabilising molecule for use in permeabilising vasculature of a tumour for treating, detecting or diagnosing said tumour wherein said tumour vasculature permeabilising molecule is formulated for systemic administration to said patient. A composition comprising a tumour vasculature permeabilising molecule and an appropriate anticancer agent or imaging agent, and a method of treatment or a method of detecting the presence or absence of a tumour are also provided.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: September 5, 2023
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Daniel Anthony, Nicola Sibson, Len Seymour, Kerry Fisher
  • Patent number: 11693003
    Abstract: The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 4, 2023
    Assignees: Hospices Civil de Lyon, Universite Claude Bernard Lyon 1, Eurobio Scientific
    Inventors: Pierre Miossec, Ndieme Thiam, Jean-Jacques Pin
  • Patent number: 11649280
    Abstract: The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: May 16, 2023
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Victor H. Obungu, Andrew Dixon Skora, Ming Ye
  • Patent number: 11541103
    Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: January 3, 2023
    Assignee: Amgen Inc.
    Inventors: Khaled M. K. Z. Ali, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Ian Foltz, Zhulun Wang, Darren Bates, Marissa Mock, Shunsuke Takenaka
  • Patent number: 11534490
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: December 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • Patent number: 11534491
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: December 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • Patent number: 11529415
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: December 20, 2022
    Assignee: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Patent number: 11517611
    Abstract: The present invention is directed to compositions including the cytokines IL-18 and IL-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier. The compositions can farther include other interleukins such as IL-1?, and IL-1? can be used as a combination therapy with either IL-18 or IL-22 or biologically active fragments or variants thereof.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: December 6, 2022
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Andrew T. Gewirtz, Benyue Zhang
  • Patent number: 11505612
    Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: November 22, 2022
    Assignee: AMGEN K-A, INC.
    Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres